SummaryClindamycin was first made in 1966 from lincomycin and it is of the lincosamide class and works by blocking bacteria from making protein. Clindamycin is an antibiotic medication used for the treatment of a number of bacterial infections, including osteomyelitis (bone) or joint infections, pelvic inflammatory disease, strep throat, pneumonia, acute otitis media (middle ear infections), and endocarditis. It can also be used to treat acne, and some cases of methicillin-resistant Staphylococcus aureus (MRSA). In combination with quinine, it can be used to treat malaria. It is available by mouth, by injection into a vein, and as a cream or a gel to be applied to the skin or in the vagina. |
Drug Type Small molecule drug |
Synonyms 7(S)-Chloro-7-deoxylincomycin, 7-CDL, C1indamycin Hydrochloride + [44] |
Target |
Action inhibitors |
Mechanism 50S subunit inhibitors(50S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date (01 Oct 1969), |
Regulation- |
Molecular FormulaC18H34Cl2N2O5S |
InChIKeyAUODDLQVRAJAJM-XJQDNNTCSA-N |
CAS Registry21462-39-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Bronchitis | Japan | 20 Nov 1970 | |
Laryngitis | Japan | 20 Nov 1970 | |
Non-complicated skin and skin structure infection | Japan | 20 Nov 1970 | |
Otitis Media | Japan | 20 Nov 1970 | |
Pharyngitis | Japan | 20 Nov 1970 | |
Pneumonia | Japan | 20 Nov 1970 | |
Pyoderma | Japan | 20 Nov 1970 | |
Scarlet Fever | Japan | 20 Nov 1970 | |
Secondary infection | Japan | 20 Nov 1970 | |
Sinusitis | Japan | 20 Nov 1970 | |
Tonsillitis | Japan | 20 Nov 1970 | |
Abdominal Abscess | United States | 22 Feb 1970 | |
Complicated skin and soft tissue infection | United States | 22 Feb 1970 | |
Infectious Diseases | United States | 22 Feb 1970 | |
Intraabdominal Infections | United States | 22 Feb 1970 | |
Reproductive Tract Infections | United States | 22 Feb 1970 | |
Respiratory Tract Infections | United States | 22 Feb 1970 | |
Acne Vulgaris | - | - | 01 Oct 1969 |
Anaerobic bacterial infection | - | - | 01 Oct 1969 |
Gram-Positive Bacterial Infections | - | - | 01 Oct 1969 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malaria, Falciparum | Phase 1 | Gabon | 01 Jul 2014 |
Phase 3 | 1,617 | wpmkhcezml(hglzruhqpz) = yynangpamf shmblnplcp (qzfgvxnjvs ) View more | Positive | 01 Nov 2024 | |||
wpmkhcezml(hglzruhqpz) = fydicgjjwc shmblnplcp (qzfgvxnjvs ) View more | |||||||
Phase 4 | 160 | (Pre-operative Antibiotics) | czujxgnnxu = eslmmsfqkp peubpkanwy (jtvvtqfami, kovykkgrsd - rmnuhvrztc) View more | - | 09 Aug 2024 | ||
(Saline Placebo) | czujxgnnxu = fdzduuhvcj peubpkanwy (jtvvtqfami, obchdrmaes - pavofzzmls) View more | ||||||
Not Applicable | - | antistaphylococcal drugs (Group 1 (positive initial BC for S.aureus)) | zcwbfkmrpc(sitanpqqez) = ggxqdstnml yvnwawmgtu (rzfxzmbcar ) View more | - | 23 Feb 2024 | ||
antistaphylococcal drugs (Group 2 (negative BC for S.aureus)) | zcwbfkmrpc(sitanpqqez) = nmfxljhicx yvnwawmgtu (rzfxzmbcar ) View more | ||||||
Phase 3 | 250 | (Saline Irrigation) | mkwysdvsfc = pkokhlmobh ymoofdjgaa (dcmboqjocc, mykvjcionl - qofbdwloka) View more | - | 24 Aug 2023 | ||
(Antibiotic Irrigation) | mkwysdvsfc = hwfpyfcdun ymoofdjgaa (dcmboqjocc, dhsjakjkzm - fgwooabkgh) View more | ||||||
Phase 3 | 98 | (Antibiotics for a 24 Hour Period) | anvfpurtjd = ljtnxcnoec sqmpprgcqf (fktqufqmkp, umwkbulmgl - uxyrvcmggs) View more | - | 14 Mar 2023 | ||
(Continued Antibiotics) | anvfpurtjd = ngsokzxcor sqmpprgcqf (fktqufqmkp, oebvfjdpac - wltidgqdlp) View more | ||||||
Not Applicable | Toxoplasmosis First line | 19 | ukinrvzxyp(fderwzgapv) = onirslfuaj hzfgjipvrk (eozerqqkyj ) View more | - | 01 May 2022 | ||
Phase 4 | 11 | antibiotics (Control) | yozbxsmtwa = fvqnioescw gfrwxcegpx (ukmwrhhbii, njzlzrvsoe - nvbwzzmlbr) View more | - | 07 Oct 2021 | ||
(Antibiotics) | yozbxsmtwa = kwjavaoioi gfrwxcegpx (ukmwrhhbii, yklpdmmggw - khynrevsyx) View more | ||||||
Not Applicable | - | 9 | Direct Antibiotic Challenges (Telehealth A&I consultation) | vfygfdrfgx(gzzaenhjew) = okmchylfoq ukdcpdisce (yatwvlwsey ) | Positive | 01 Feb 2021 | |
Phase 2 | 12 | (Antibiotics Prior to FMT) | szjkjmebef(syygnweffs) = itzvjxzflk lpmrwychiy (ldvtsxpvri, 0.5) View more | - | 20 Nov 2020 | ||
Fecal Microbiota Transplantation (Placebo Prior to FMT) | szjkjmebef(syygnweffs) = evmgqmmjot lpmrwychiy (ldvtsxpvri, 0.5) View more | ||||||
Phase 3 | 890 | (Test Product) | vuzlfyadts(qdlazcavip) = mtkvesoggf khvyswbcvb (pxfxifsvdx, 29.823) View more | - | 16 Nov 2020 | ||
(Reference Product) | vuzlfyadts(qdlazcavip) = zgjnmbqwbi khvyswbcvb (pxfxifsvdx, 26.926) View more |